NCT00344123View on ClinicalTrials.gov

Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
HIV Infections
Interventions
DRUG

Tipranavir/Ritonavir

"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."

DRUG

Rosuvastatin

"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.."

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Johns Hopkins University

OTHER